{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:09:43Z","timestamp":1792469383856,"version":"4.5.0"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-005"],"award-info":[{"award-number":["2021-I2M-1-005"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003983"],"award-info":[{"award-number":["82003983"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073853"],"award-info":[{"award-number":["82073853"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82141204"],"award-info":[{"award-number":["82141204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.phrs.2022.106238","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T01:59:14Z","timestamp":1651283954000},"page":"106238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"special_numbering":"C","title":["Immunity and inflammation in pulmonary arterial hypertension: From pathophysiology mechanisms to treatment perspective"],"prefix":"10.1016","volume":"180","author":[{"given":"Ran-ran","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-yi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-mei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-cai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiu-liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-hua","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-hua","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02148-2018","article-title":"An overview of the 6th world symposium on pulmonary hypertension","volume":"53","author":"Galie","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib2","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"10","key":"10.1016\/j.phrs.2022.106238_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrcardio.2017.84","article-title":"Epidemiology and treatment of pulmonary arterial hypertension","volume":"14","author":"Lau","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12016-011-8265-z","article-title":"The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension","volume":"44","author":"Kherbeck","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.berh.2016.03.004","article-title":"Connective tissue disease-related pulmonary arterial hypertension","volume":"30","author":"Thakkar","year":"2016","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"11","key":"10.1016\/j.phrs.2022.106238_bib8","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","article-title":"Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach","volume":"62","author":"Mukerjee","year":"2003","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.phrs.2022.106238_bib9","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1002\/art.21433","article-title":"Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study","volume":"52","author":"Hachulla","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.phrs.2022.106238_bib10","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1177\/0961203313499086","article-title":"Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic\u00a0lupus erythematosus","volume":"22","author":"Li","year":"2013","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.phrs.2022.106238_bib11","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/rheumatology\/kep203","article-title":"Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus","volume":"48","author":"Prabu","year":"2009","journal-title":"Rheumatology"},{"issue":"122","key":"10.1016\/j.phrs.2022.106238_bib12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1183\/09059180.00003811","article-title":"Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus","volume":"20","author":"Johnson","year":"2011","journal-title":"Eur. Respir. Rev."},{"issue":"12","key":"10.1016\/j.phrs.2022.106238_bib13","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1177\/0961203313505010","article-title":"Pulmonary arterial hypertension in SLE: what do we know?","volume":"22","author":"Prabu","year":"2013","journal-title":"Lupus"},{"issue":"5","key":"10.1016\/j.phrs.2022.106238_bib14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2019-216274","article-title":"Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis","volume":"79","author":"Kuwana","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1378\/chest.10-2327","article-title":"Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era","volume":"140","author":"Zhang","year":"2011","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.phrs.2022.106238_bib16","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1183\/09031936.00182813","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients","volume":"44","author":"Hao","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.phrs.2022.106238_bib17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/1756-185X.13478","article-title":"Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: baseline characteristics and risk factors","volume":"22","author":"Zhang","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.phrs.2022.106238_bib18","doi-asserted-by":"crossref","first-page":"j5492","DOI":"10.1136\/bmj.j5492","article-title":"Pulmonary arterial hypertension: pathogenesis and clinical management","volume":"360","author":"Thenappan","year":"2018","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib19","article-title":"Inflammation, immunity, and vascular remodeling in pulmonary hypertension; evidence for complement involvement?","volume":"2020","author":"Frid","year":"2020","journal-title":"Glob. Cardiol. Sci. Pract."},{"issue":"11","key":"10.1016\/j.phrs.2022.106238_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112338","article-title":"Perivascular inflammation in pulmonary arterial hypertension","volume":"9","author":"Hu","year":"2020","journal-title":"Cells"},{"issue":"7203","key":"10.1016\/j.phrs.2022.106238_bib21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature07201","article-title":"Origin and physiological roles of inflammation","volume":"454","author":"Medzhitov","year":"2008","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.phrs.2022.106238_bib22","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/eji.201546178","article-title":"Aging of the immune system: focus on inflammation and vaccination","volume":"46","author":"Pinti","year":"2016","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/2045893218757596","article-title":"Inflammation and autoimmunity in pulmonary hypertension: is there a role for endothelial adhesion molecules? (2017 Grover conference series)","volume":"8","author":"Kuebler","year":"2018","journal-title":"Pulm. Circ."},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4049\/jimmunol.1303048","article-title":"Adventitial fibroblasts induce a distinct proinflammatory\/profibrotic macrophage phenotype in pulmonary hypertension","volume":"193","author":"El Kasmi","year":"2014","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1164\/rccm.201201-0164OC","article-title":"Modern age pathology of pulmonary arterial hypertension","volume":"186","author":"Stacher","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10","key":"10.1016\/j.phrs.2022.106238_bib26","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.201608-1630PP","article-title":"The roles of immunity in the prevention and evolution of pulmonary arterial hypertension","volume":"195","author":"Nicolls","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1177\/1535370218824101","article-title":"Pulmonary arterial hypertension in connective tissue disorders: pathophysiology and treatment","volume":"244","author":"Zanatta","year":"2019","journal-title":"Exp. Biol. Med."},{"issue":"12","key":"10.1016\/j.phrs.2022.106238_bib28","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/abbs\/gmx095","article-title":"Immune cells and autoantibodies in pulmonary arterial hypertension","volume":"49","author":"Li","year":"2017","journal-title":"Acta Biochim. Biophys. Sin."},{"issue":"4","key":"10.1016\/j.phrs.2022.106238_bib29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1084\/jem.20071258","article-title":"Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category","volume":"205","author":"Luger","year":"2008","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib30","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/CIRCRESAHA.108.182014","article-title":"Interleukin-6 overexpression induces pulmonary hypertension","volume":"104","author":"Steiner","year":"2009","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.phrs.2022.106238_bib31","doi-asserted-by":"crossref","first-page":"L609","DOI":"10.1152\/ajplung.00531.2016","article-title":"Central role of T helper 17 cells in chronic hypoxia-induced pulmonary hypertension","volume":"312","author":"Maston","year":"2017","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib32","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.rmed.2009.10.004","article-title":"T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension","volume":"104","author":"Austin","year":"2010","journal-title":"Respir. Med."},{"issue":"23","key":"10.1016\/j.phrs.2022.106238_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014201","article-title":"The role of regulatory T cells in pulmonary arterial hypertension","volume":"8","author":"Qiu","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"4","key":"10.1016\/j.phrs.2022.106238_bib34","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.apsb.2020.12.018","article-title":"Biological drug and drug delivery-mediated immunotherapy","volume":"11","author":"Xiao","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"8","key":"10.1016\/j.phrs.2022.106238_bib35","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/CIRCRESAHA.110.236927","article-title":"Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension","volume":"109","author":"Tamosiuniene","year":"2011","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2022.106238_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.684657","article-title":"The role of regulatory T cells in pulmonary arterial hypertension","volume":"12","author":"Tian","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib37","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.0300-9475.2004.01370.x","article-title":"Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus","volume":"59","author":"Liu","year":"2004","journal-title":"Scand. J. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1521-6616(03)00062-7","article-title":"Distinct immune profiles characterize patients with diffuse or limited systemic sclerosis","volume":"108","author":"Ingegnoli","year":"2003","journal-title":"Clin. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000024324","article-title":"Athymic nude rats develop severe pulmonary hypertension following monocrotaline administration","volume":"121","author":"Miyata","year":"2000","journal-title":"Int. Arch. Allergy Immunol."},{"issue":"12","key":"10.1016\/j.phrs.2022.106238_bib40","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1164\/rccm.200608-1189OC","article-title":"Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling","volume":"175","author":"Taraseviciene-Stewart","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.phrs.2022.106238_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1465-9921-9-20","article-title":"Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study","volume":"9","author":"Ulrich","year":"2008","journal-title":"Respir. Res."},{"issue":"5","key":"10.1016\/j.phrs.2022.106238_bib42","doi-asserted-by":"crossref","first-page":"L710","DOI":"10.1152\/ajplung.00311.2016","article-title":"The mast cell-B cell axis in lung vascular remodeling and pulmonary hypertension","volume":"312","author":"Breitling","year":"2017","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: a multicenter, double-blind, randomized, placebo-controlled trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"8","key":"10.1016\/j.phrs.2022.106238_bib44","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1177\/0961203307087610","article-title":"Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report","volume":"17","author":"Hennigan","year":"2008","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.phrs.2022.106238_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131923","article-title":"Pulmonary macrophages attenuate hypoxic pulmonary vasoconstriction via beta3AR\/iNOS pathway in rats exposed to chronic intermittent hypoxia","volume":"10","author":"Nagai","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib46","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4103\/2045-8932.97613","article-title":"Activation of the unfolded protein response is associated with pulmonary hypertension","volume":"2","author":"Yeager","year":"2012","journal-title":"Pulm. Circ."},{"issue":"200","key":"10.1016\/j.phrs.2022.106238_bib47","doi-asserted-by":"crossref","first-page":"200ra117","DOI":"10.1126\/scitranslmed.3006674","article-title":"Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension","volume":"5","author":"Tian","year":"2013","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib48","doi-asserted-by":"crossref","first-page":"906","DOI":"10.4049\/jimmunol.1200257","article-title":"Macrophage dectin-1 expression is controlled by leukotriene B4 via a GM-CSF\/PU.1 axis","volume":"189","author":"Serezani","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2022.106238_bib49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-immunol-071719-094903","article-title":"Mast cells in inflammation and disease: recent progress and ongoing concerns","volume":"38","author":"Galli","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.phrs.2022.106238_bib50","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1465-9921-12-60","article-title":"Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats","volume":"12","author":"Dahal","year":"2011","journal-title":"Respir. Res."},{"issue":"6","key":"10.1016\/j.phrs.2022.106238_bib51","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1183\/09031936.00043310","article-title":"Mast cells promote lung vascular remodelling in pulmonary hypertension","volume":"37","author":"Hoffmann","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1164\/rccm.201006-0905OC","article-title":"C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension","volume":"184","author":"Montani","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib53","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1378\/chest.11-0663","article-title":"Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension","volume":"141","author":"Bartelds","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056773","article-title":"Mast cell dependent vascular changes associated with an acute response to cold immersion in primary contact urticaria","volume":"8","author":"Meyer","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib55","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12016-019-08769-2","article-title":"Mast cell biology at molecular level: a comprehensive review","volume":"58","author":"Elieh Ali Komi","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.phrs.2022.106238_bib56","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fimmu.2020.00924","article-title":"Dendritic cells and their role in immunotherapy","volume":"11","author":"Gardner","year":"2020","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.phrs.2022.106238_bib57","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.phrs.2022.106238_bib58","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/nm1097","article-title":"Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A","volume":"10","author":"Conejo-Garcia","year":"2004","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib59","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1183\/09031936.00094706","article-title":"Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension","volume":"29","author":"Perros","year":"2007","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.phrs.2022.106238_bib60","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10875-009-9322-8","article-title":"Impairment of monocyte-derived dendritic cells in idiopathic pulmonary arterial hypertension","volume":"29","author":"Wang","year":"2009","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.phrs.2022.106238_bib61","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.semcdb.2014.04.020","article-title":"Modulation of tolerogenic dendritic cells and autoimmunity","volume":"41","author":"Kim","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"issue":"8","key":"10.1016\/j.phrs.2022.106238_bib62","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nri3477","article-title":"The role of dendritic cells in autoimmunity","volume":"13","author":"Ganguly","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2022.106238_bib63","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1146\/annurev.immunol.26.021607.090320","article-title":"The master switch: the role of mast cells in autoimmunity and tolerance","volume":"26","author":"Sayed","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.phrs.2022.106238_bib64","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-065X.2007.00519.x","article-title":"Differential release of mast cell mediators and the pathogenesis of inflammation","volume":"217","author":"Theoharides","year":"2007","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.phrs.2022.106238_bib65","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.iy.06.040188.002413","article-title":"Molecular regulation of B lymphocyte response","volume":"6","author":"Kishimoto","year":"1988","journal-title":"Annu. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.phrs.2022.106238_bib66","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","article-title":"Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension","volume":"122","author":"Soon","year":"2010","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.phrs.2022.106238_bib67","doi-asserted-by":"crossref","DOI":"10.1177\/20458940211051292","article-title":"Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines","volume":"11","author":"Zhong","year":"2021","journal-title":"Pulm. Circ."},{"issue":"4","key":"10.1016\/j.phrs.2022.106238_bib68","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1046\/j.1440-1843.2003.00491.x","article-title":"Effects of IL-1beta, TNF-alpha, and macrophage migration inhibitory factor on prostacyclin synthesis in rat pulmonary artery smooth muscle cells","volume":"8","author":"Itoh","year":"2003","journal-title":"Respirology"},{"key":"10.1016\/j.phrs.2022.106238_bib69","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1465-9921-15-47","article-title":"Inflammatory cytokines in pulmonary hypertension","volume":"15","author":"Groth","year":"2014","journal-title":"Respir. Res."},{"issue":"6","key":"10.1016\/j.phrs.2022.106238_bib70","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib71","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0952-3278(97)90532-9","article-title":"Cytokines and lipopolysaccharide enhance basal and thrombin-stimulated production of PGI2 by cultured human pulmonary artery smooth muscle cells","volume":"56","author":"Wen","year":"1997","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib72","doi-asserted-by":"crossref","first-page":"L553","DOI":"10.1152\/ajplung.00044.2006","article-title":"IL-1beta, BK, and TGF-beta1 attenuate PGI2-mediated cAMP formation in human pulmonary artery smooth muscle cells by multiple mechanisms involving p38 MAP kinase and PKA","volume":"294","author":"El-Haroun","year":"2008","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106238_bib73","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01761-2019","article-title":"Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension","volume":"55","author":"Simpson","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"Suppl. 6","key":"10.1016\/j.phrs.2022.106238_bib74","doi-asserted-by":"crossref","first-page":"572S","DOI":"10.1378\/chest.128.6_suppl.572S-a","article-title":"Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice","volume":"128","author":"Golembeski","year":"2005","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.phrs.2022.106238_bib75","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1172\/JCI96462","article-title":"Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension","volume":"128","author":"Tamura","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.phrs.2022.106238_bib76","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00314-2020","article-title":"IL-6 in pulmonary hypertension: why novel is not always best","volume":"55","author":"Toshner","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib77","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1183\/09031936.00174908","article-title":"Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension","volume":"34","author":"Selimovic","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"8","key":"10.1016\/j.phrs.2022.106238_bib78","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.healun.2012.04.008","article-title":"Type I immune response cytokine-chemokine cascade is associated with pulmonary arterial hypertension","volume":"31","author":"Ross","year":"2012","journal-title":"J. Heart Lung Transpl."},{"issue":"4","key":"10.1016\/j.phrs.2022.106238_bib79","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1164\/ajrccm.165.4.2012112","article-title":"Chemokine RANTES in severe pulmonary arterial hypertension","volume":"165","author":"Dorfmuller","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.phrs.2022.106238_bib80","first-page":"497","article-title":"Anti-endothelial cell antibodies in connective tissue diseases associated with pulmonary arterial hypertension","volume":"6","author":"Liu","year":"2014","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.phrs.2022.106238_bib81","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.yjmcc.2018.01.016","article-title":"CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation","volume":"116","author":"Nie","year":"2018","journal-title":"J. Mol. Cell Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib82","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pcad.2012.07.006","article-title":"Immune and inflammatory mechanisms in pulmonary arterial hypertension","volume":"55","author":"El Chami","year":"2012","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"10","key":"10.1016\/j.phrs.2022.106238_bib83","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1164\/rccm.200610-1559OC","article-title":"Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension","volume":"176","author":"Sanchez","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.phrs.2022.106238_bib84","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1165\/rcmb.2012-0532OC","article-title":"Protective role of IL-6 in vascular remodeling in Schistosoma pulmonary hypertension","volume":"49","author":"Graham","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"10","key":"10.1016\/j.phrs.2022.106238_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075415","article-title":"Nuclear factor kappa-B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension","volume":"8","author":"Price","year":"2013","journal-title":"PLoS One"},{"issue":"11\u201312","key":"10.1016\/j.phrs.2022.106238_bib86","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s00424-016-1899-1","article-title":"BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators","volume":"468","author":"Vengethasamy","year":"2016","journal-title":"Pflug. Arch."},{"issue":"5","key":"10.1016\/j.phrs.2022.106238_bib87","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1172\/JCI120415","article-title":"Classical IL-6 signaling: a promising therapeutic target for pulmonary arterial hypertension","volume":"128","author":"Pullamsetti","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib88","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.201707-1370OC","article-title":"Toll-like receptor 3 is a therapeutic target for pulmonary hypertension","volume":"199","author":"Farkas","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"20","key":"10.1016\/j.phrs.2022.106238_bib89","doi-asserted-by":"crossref","first-page":"E2677","DOI":"10.1073\/pnas.1424774112","article-title":"Interleukin-6\/interleukin-21 signaling axis is critical in the pathogenesis of pulmonary arterial hypertension","volume":"112","author":"Hashimoto-Kataoka","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib90","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1183\/09031936.00151313","article-title":"Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension","volume":"43","author":"Cracowski","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.phrs.2022.106238_bib91","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1164\/ajrccm.151.5.7735624","article-title":"Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension","volume":"151","author":"Humbert","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib92","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1440-1843.2006.00821.x","article-title":"Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension","volume":"11","author":"Itoh","year":"2006","journal-title":"Respirology"},{"issue":"5","key":"10.1016\/j.phrs.2022.106238_bib93","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14017431.2017.1359419","article-title":"Angiogenic and inflammatory biomarkers in the differentiation of pulmonary hypertension","volume":"51","author":"Saleby","year":"2017","journal-title":"Scand. Cardiovasc. J."},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib94","doi-asserted-by":"crossref","DOI":"10.1177\/2045894018794051","article-title":"Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension","volume":"8","author":"Joshi","year":"2018","journal-title":"Pulm. Circ."},{"issue":"10","key":"10.1016\/j.phrs.2022.106238_bib95","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1164\/rccm.2106007","article-title":"CX(3)C chemokine fractalkine in pulmonary arterial hypertension","volume":"165","author":"Balabanian","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"9","key":"10.1016\/j.phrs.2022.106238_bib96","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/thx.2004.029082","article-title":"Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension","volume":"60","author":"Tamby","year":"2005","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.phrs.2022.106238_bib97","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.06.00152705","article-title":"Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension","volume":"28","author":"Tamby","year":"2006","journal-title":"Eur. Respir. J."},{"issue":"10","key":"10.1016\/j.phrs.2022.106238_bib98","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1164\/rccm.200707-1015OC","article-title":"Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension","volume":"177","author":"Terrier","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"8","key":"10.1016\/j.phrs.2022.106238_bib99","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.drudis.2014.04.007","article-title":"Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first","volume":"19","author":"Cohen-Kaminsky","year":"2014","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.phrs.2022.106238_bib100","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.semarthrit.2014.11.006","article-title":"Antinuclear antibody-negative systemic sclerosis","volume":"44","author":"Salazar","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib101","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1172\/JCI118377","article-title":"IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines","volume":"97","author":"Carvalho","year":"1996","journal-title":"J. Clin. Investig."},{"issue":"8","key":"10.1016\/j.phrs.2022.106238_bib102","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/14779072.2016.1180976","article-title":"Challenges and opportunities in treating inflammation associated with pulmonary hypertension","volume":"14","author":"Voelkel","year":"2016","journal-title":"Expert Rev. Cardiovasc. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2022.106238_bib103","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/art.10361","article-title":"Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis","volume":"46","author":"Chizzolini","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.phrs.2022.106238_bib104","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/rheumatology\/kem241","article-title":"Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts","volume":"46","author":"Fineschi","year":"2007","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.phrs.2022.106238_bib105","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1002\/art.24049","article-title":"Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4","volume":"58","author":"Fineschi","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.phrs.2022.106238_bib106","first-page":"1688","article-title":"Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis","volume":"22","author":"Fritzler","year":"1995","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib107","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1164\/ajrccm.155.1.9001324","article-title":"Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7","volume":"155","author":"Morse","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib108","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1365-2249.2000.01320.x","article-title":"Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35","volume":"121","author":"Grigolo","year":"2000","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib109","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/art.10914","article-title":"Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension","volume":"49","author":"Ulanet","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2022.106238_bib110","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ijcard.2017.01.097","article-title":"Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: a cohort study in China","volume":"236","author":"Zhao","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"7","key":"10.1016\/j.phrs.2022.106238_bib111","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3899\/jrheum.130984","article-title":"Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center","volume":"41","author":"Artim-Esen","year":"2014","journal-title":"J. Rheumatol."},{"issue":"9","key":"10.1016\/j.phrs.2022.106238_bib112","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/1756-185X.12645","article-title":"Survival and prognostic factors in patients with connective tissue disease-associated pulmonary hypertension diagnosed by echocardiography: results from a Korean nationwide registry","volume":"20","author":"Kang","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.phrs.2022.106238_bib113","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/854941","article-title":"Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction","volume":"2012","author":"Dhala","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.phrs.2022.106238_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114147","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective","volume":"180","author":"Bindu","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib115","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02449-2016","article-title":"Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension","volume":"50","author":"Spiekerkoetter","year":"2017","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib116","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1183\/09031936.06.00095705","article-title":"A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension","volume":"27","author":"Robbins","year":"2006","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib117","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0014-4800(89)90040-3","article-title":"Comparative effects of isosorbide dinitrate, prednisolone, indomethacin, and elastase on the development of monocrotaline-induced pulmonary hypertension","volume":"50","author":"Kato","year":"1989","journal-title":"Exp. Mol. Pathol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106238_bib118","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1183\/09031936.00028310","article-title":"Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats","volume":"37","author":"Price","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib119","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1378\/chest.130.1.182","article-title":"Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension","volume":"130","author":"Sanchez","year":"2006","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.phrs.2022.106238_bib120","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1253\/circj.CJ-11-0473","article-title":"Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease","volume":"75","author":"Miyamichi-Yamamoto","year":"2011","journal-title":"Circ. J."},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib121","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/cmdc.201500269","article-title":"Potent and selective human neutrophil elastase inhibitors with novel equatorial ring topology: in vivo efficacy of the polar pyrimidopyridazine BAY-8040 in a pulmonary arterial hypertension rat model","volume":"11","author":"von Nussbaum","year":"2016","journal-title":"ChemMedChem"},{"issue":"5","key":"10.1016\/j.phrs.2022.106238_bib122","first-page":"375","article-title":"Effect of elastase inhibitor on pulmonary hypertension induced by monocrotaline","volume":"42","author":"Fu","year":"2004","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"15","key":"10.1016\/j.phrs.2022.106238_bib123","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/0006-2952(89)90084-1","article-title":"Monocrotaline-induced cardiopulmonary injury in rats. Modification by the neutrophil elastase inhibitor SC39026","volume":"38","author":"Molteni","year":"1989","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.phrs.2022.106238_bib124","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1164\/rccm.201504-0686ED","article-title":"Elafin in pulmonary arterial hypertension. Beyond targeting elastases","volume":"191","author":"Chun","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.phrs.2022.106238_bib125","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/hc0402.102866","article-title":"Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension","volume":"105","author":"Zaidi","year":"2002","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.phrs.2022.106238_bib126","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1164\/rccm.201412-2291OC","article-title":"Elafin reverses pulmonary hypertension via caveolin-1-dependent bone morphogenetic protein signaling","volume":"191","author":"Nickel","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"46","key":"10.1016\/j.phrs.2022.106238_bib127","doi-asserted-by":"crossref","first-page":"34730","DOI":"10.1074\/jbc.M604844200","article-title":"Elafin prevents lipopolysaccharide-induced AP-1 and NF-kappaB activation via an effect on the ubiquitin-proteasome pathway","volume":"281","author":"Butler","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.phrs.2022.106238_bib128","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1172\/JCI65592","article-title":"FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension","volume":"123","author":"Spiekerkoetter","year":"2013","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.phrs.2022.106238_bib129","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1165\/rcmb.2012-0429OC","article-title":"Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension","volume":"48","author":"Houssaini","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106238_bib130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4103\/0378-6323.32888","article-title":"A modified two-step treatment for actinomycetoma","volume":"73","author":"Ramam","year":"2007","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106238_bib131","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1378\/chest.09-2435","article-title":"Dramatic improvement in pulmonary hypertension with rapamycin","volume":"138","author":"Wessler","year":"2010","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib132","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9020561","article-title":"Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an immunological perspective","volume":"9","author":"Koudstaal","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.phrs.2022.106238_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118877","article-title":"Sacubitril\/valsartan treatment relieved the progression of established pulmonary hypertension in rat model and its mechanism","volume":"266","author":"Liu","year":"2021","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib134","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3892\/ijmm.2020.4813","article-title":"Astragaloside IV blocks monocrotalineinduced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling","volume":"47","author":"Jin","year":"2021","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib135","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/10641963.2020.1860080","article-title":"Perillyl alcohol suppresses monocrotaline-induced pulmonary arterial hypertension in rats via anti-remodeling, anti-oxidant, and anti-inflammatory effects","volume":"43","author":"Beik","year":"2021","journal-title":"Clin. Exp. Hypertens."},{"issue":"6","key":"10.1016\/j.phrs.2022.106238_bib136","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/FJC.0000000000001015","article-title":"Quercetin, perillyl alcohol, and berberine ameliorate right ventricular disorders in experimental pulmonary arterial hypertension: effects on miR-204, miR-27a, fibrotic, apoptotic, and inflammatory factors","volume":"77","author":"Rajabi","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106238_bib137","doi-asserted-by":"crossref","first-page":"1841527","DOI":"10.1155\/2020\/1841527","article-title":"Resveratrol prevents right ventricle remodeling and dysfunction in monocrotaline-induced pulmonary arterial hypertension with a limited improvement in the lung vasculature","volume":"2020","author":"Vazquez-Garza","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib138","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1536\/ihj.19-096","article-title":"Alginate oligosaccharide alleviates monocrotaline-induced pulmonary hypertension via anti-oxidant and anti-inflammation pathways in rats","volume":"61","author":"Feng","year":"2020","journal-title":"Int. Heart J."},{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib139","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/CM9.0000000000000577","article-title":"3-Bromopyruvate alleviates the development of monocrotaline-induced rat pulmonary arterial hypertension by decreasing aerobic glycolysis, inducing apoptosis, and suppressing inflammation","volume":"133","author":"Liu","year":"2020","journal-title":"Chin. Med. J."},{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib140","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12931-021-01875-w","article-title":"Reversal of pulmonary arterial hypertension and neointimal formation by kinin B1 receptor blockade","volume":"22","author":"Rampa","year":"2021","journal-title":"Respir. Res."},{"issue":"3","key":"10.1016\/j.phrs.2022.106238_bib141","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s10753-018-0747-1","article-title":"HGF reduces disease severity and inflammation by attenuating the NF-kappaB signaling in a rat model of pulmonary artery hypertension","volume":"41","author":"Pang","year":"2018","journal-title":"Inflammation"},{"issue":"4","key":"10.1016\/j.phrs.2022.106238_bib142","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1165\/rcmb.2018-0232OC","article-title":"Carbonic anhydrase inhibition ameliorates inflammation and experimental pulmonary hypertension","volume":"61","author":"Hudalla","year":"2019","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.phrs.2022.106238_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118709","article-title":"Interferon regulatory factor 7 inhibits rat vascular smooth muscle cell proliferation and inflammation in monocrotaline-induced pulmonary hypertension","volume":"264","author":"Deng","year":"2021","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.phrs.2022.106238_bib144","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/CIRCRESAHA.115.301130","article-title":"The metabolic theory of pulmonary arterial hypertension","volume":"115","author":"Paulin","year":"2014","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106238_bib145","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/2045893217701438","article-title":"The cancer theory of pulmonary arterial hypertension","volume":"7","author":"Boucherat","year":"2017","journal-title":"Pulm. Circ."},{"issue":"4","key":"10.1016\/j.phrs.2022.106238_bib146","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40256-015-0125-4","article-title":"Novel targets of drug treatment for pulmonary hypertension","volume":"15","author":"Hu","year":"2015","journal-title":"Am. J. Cardiovasc. Drugs"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822001839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822001839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:31:08Z","timestamp":1760913068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822001839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":146,"alternative-id":["S1043661822001839"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106238","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunity and inflammation in pulmonary arterial hypertension: From pathophysiology mechanisms to treatment perspective","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106238"}}